Abstract:Tyrosine kinases are known to play a role in tumour growth and proliferation, and they have become common drug targets. Tyrosine kinase inhibitors (TKIs) prohibit associated kinases from phosphorylating tyrosine residues in their substrates, preventing downstream signaling pathways from being activated. Multiple robust and well-tolerated TKIs targeting single or multiple targets, including EGFR, ALK, ROS1, HER2, NTRK, VEGFR, RET, MET, MEK, FGFR, PDGFR, and KIT, have been developed over the last two decades, contributing to our understanding of precision cancer medicine based on a patient's genetic alteration profile. The epidermal growth factor receptor (EGFR) family consists of four transmembrane tyrosine kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3, and Her4/ErbB4) and thirteen polypeptide ligands produced by them. Multiple solid tumours, including breast, pancreatic, head and neck, kidney, vaginal, renal, colon, and non-small cell lung cancer, overexpress EGFRs. Overexpression of these genes stimulates downstream signaling channels, causing cell proliferation, differentiation, cell cycle progression, angiogenesis, cell motility, and apoptosis inhibition. EGFRs' high expression and/or adaptive activation coincide with the pathogenesis and development of many tumours, making them appealing candidates for both diagnosis and therapy. Several strategies for targeting these receptors and/or the EGFR-mediated effects in cancer cells have been established. The majority of methods include the development of anti-EGFR antibodies and/or small-molecule EGFR inhibitors. This review presents the recent advances in EGFR TKIs and their role in the treatment of cancer.

Advances in Anti-Tumor Therapy Targeting the EGFR Family of Receptor Tyrosine Kinases

Development of Egfr Family Small Molecule Inhibitors for Anticancer Intervention: an Overview of Approved Drugs and Clinical Candidates

Targeting the EGFR signaling pathway in cancer therapy

[Tumor Biotherapy Based on Epidermal Growth Factor Receptor As a Target].

Targeted Therapies for Patients with Advanced NSCLC Harboring Wild-Type EGFR: What’s New and What’s Enough

Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy

Progress on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor for Treatment of Advanced Non-Small Cell Lung Cancer

Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of Cancer: A Review

Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

The EGF receptor family as targets for cancer therapy

The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Targeting RON Receptor Tyrosine Kinase for Treatment of Advanced Solid Cancers: Antibody–drug Conjugates As Lead Drug Candidates for Clinical Trials

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Update on Targeting EGFR in Advanced Non-Small-cell Lung Cancer

Recent Advances on Epidermal Growth Factor Receptor as a Molecular Target for Breast Cancer Therapeutics

Epidermal Growth Factor Receptor Family Tyrosine Kinase and Cancer Therapy

Receptor Tyrosine Kinases: Biological Functions and Anticancer Targeted Therapy

Recent Advances in Tumor Therapy Targeting FGFR

Receptor-Targeted Cancer Therapy